Sakari Hietanen
sakari.hietanen@utu.fi |
Publications
- Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study (2024)
- Acta Oncologica
(A1 Refereed original research article in a scientific journal) - Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma (2023)
- Biomedicine and Pharmacotherapy
(A1 Refereed original research article in a scientific journal) - Comorbidity of Urogynecological and Gastrointestinal Disorders in Female Patients With Lichen Sclerosus (2023)
- Journal of Lower Genital Tract Disease
(A1 Refereed original research article in a scientific journal) - Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial (2023)
- European Journal of Cancer
(A1 Refereed original research article in a scientific journal) - Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma (2023)
- Cancer Cell
(A1 Refereed original research article in a scientific journal) - Evolutionary study identifies poor prognosis HGSC patients and reveals clinically relevant targets at diagnosis and relapse2023
- International Journal of Gynecological Cancer
(Other publication) - Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes (2023)
- Clinical Cancer ResearchInternational Journal of Gynecological Cancer
(A1 Refereed original research article in a scientific journal) - (2023)
- JCO Precision OncologyJCO Precision Oncology
(A1 Refereed original research article in a scientific journal) - Multi-omics characterization of chemo-refractory high-grade serous cancerOverall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer2023
(Other publication) - Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma (2023)
(A1 Refereed original research article in a scientific journal) - (2023)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal) - Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma (2022)
- Oral Oncology
(A1 Refereed original research article in a scientific journal) - Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study (2022)
- Gynecologic Oncology
(A1 Refereed original research article in a scientific journal) - Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer (2022)
- Science Advances
(A1 Refereed original research article in a scientific journal) - Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer (2022)
- npj Precision Oncology
(A1 Refereed original research article in a scientific journal) - QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability (2022)
- Laboratory Investigation
(A1 Refereed original research article in a scientific journal) - Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality (2021)
- Scientific Reports
(A1 Refereed original research article in a scientific journal) - Agile Workflow For Interactive Analysis Of Mass Cytometry Data (2021)
- Bioinformatics
(A1 Refereed original research article in a scientific journal) - A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer (2021)
- Cancers
(A1 Refereed original research article in a scientific journal) - Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance (2021)
- Nature Communications
(A1 Refereed original research article in a scientific journal)



